Regenerative Biotechnology
Autologous Natural Killer Cells
Autologous Natural Killer cells pretreated with immune checkpoint inhibitors.
Injectable solution of autologous Natural Killer cells pretreated with nivolumab and ipilimumab to activate innate and adaptive immune response against tumor cells.
Composition
Células Natural Killer autólogas con nivolumab e ipilimumab.
Pharmaceutical form
Injectable solution.
Presentation
Single-dose vial, 4 ml.
Therapeutic properties
Activation of innate and adaptive immunity through NK cell cytotoxicity and enhancement of T lymphocytes against tumor cells.
- Activación de células NK autólogas.
- Cytotoxic destruction of tumor cells.
- Blockade of tumor immune evasion.
- Activation of specific T lymphocytes.
- Reduction of tumor growth.
- Increased tumor immune visibility.
- Support in advanced neoplasms.
- Enhancement of sustained antitumor response.
Mechanism of action & Clinical data
NK cells induce tumor apoptosis and, through PD-1 and CTLA-4 blockade, enhance innate and adaptive immune responses.